Register
Interesting Cases
eMediNexus Coverage from: 
A Rare Case of Imatinib-induced Erythroderma
Dr Rajesh Verma, Dr Biju Vasudevan, Dr Vijendran Pragasam, Dr Shekhar Neema,  29 August 2019
remove_red_eye 1318 Views
#Allergy and Immunology #Dermatology

0 Read Comments                

Imatinib, a specific tyrosine kinase inhibitor is a newer anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is generally well tolerated with few side effects. Most commonly reported adverse events are maculopapular eruptions and periorbital edema. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 52-year-old male who initially presented with a maculopapular rash and develop
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now